## National RLS Opioid Registry June 2024 Update



# **Back to Basics: Medications and Dosages**

John Winkelman, MD, PhD Sleep Disorders Clinical Research Program Massachusetts General Hospital






### This update includes 4-year information, which has been received for all RLS Registry participants.




Collection of **5- and 6-year** information is still **in progress**.

### Baseline (BL) to 4-Year (4Y) Opioid Dose Changes

#### **Morphine mg Equivalent (MME) Dose**







Methadone 52.3 %



Oxycodone 20.8 %



Hydrocodone 10.2 %



**Buprenorphine** 9.7 %



Tramadol 6.2 %

#### **Opioid Types**

Roughly the **same number** of people using **methadone** or **oxycodone** at baseline are still using those medications.

Since baseline, **6.6**% of participants have switched to **buprenorphine** as their RLS medication – **more than any other opioid**.



Morphine 5.2 %



Codeine 2.4 %



**Hydromorphone** 1.4 %




Fentanyl 0.7 %



Pentazocine 0.2 %

#### **Factors Associated with Large Dose Increases**



Switching Opioid Medications


Less than 1 Year on Opioids at Baseline


Significant Baseline Depression **Coexisting Pain Conditions** 

Adding/Removing a Dopaminergic Medication

Painful RLS at Baseline

#### **RLS and Insomnia Severity Have Remained Stable**





#### Baseline to 4-year past-week RLS severity

The IRLS questionnaire assesses RLS symptom severity over the previous 7 days, while taking current medications. This graph displays the change in symptom severity over four years of opioid treatment. There has been very little change in symptom severity, with a small increase in mild-to-moderate symptoms.



### **RLSCurbside.org**

RLS Curbside is a free, confidential, provider-toprovider forum.

The site was developed **for RLS providers**, to optimize management of complicated RLS patients. We hope this tool will enable healthcare providers to confidently treat RLS with the most effective, evidence-based, personalized treatments for their patients.

Recommend RLS Curbside to your RLS provider!



#### Thank you for your participation in the RLS Registry!

Baseline: 500

1-Yr: 471 2-Yrs: 457 3-Yrs: 441 4-Yrs: 425

5-Yrs: 365 to-date

6-Yrs: 153 to-date



10-Yrs



At 4-years, nearly all still-eligible participants enrolled at baseline (93.8%) continue participation. We hope to continue the Registry until 10-years!





We are excited to share that Dr. Winkelman presented 4-year Registry information at the recent National **SLEEP 2024** meeting in Houston, Texas!





This study is not meant to be used as clinical guidance.





Questions or comments? Please email akilty@mgh.harvard.edu or call (617) 643 - 6026.